AGGREGATION. Life sciences research is generating vast amounts of data. Genetic databases are estimated to be doubling in size every six months. The tremendous advances in genomic and molecular research, the increased availability of clinical data, internal research and development efforts, and mergers and acquisitions have all led to an explosion of data available to biotechnology and pharmaceutical companies. Jumper provides new mashup technology that allows you to easily aggregate structured data from multiple source systems for delivery to target applications.

INTEGRATION. Successful data integration is one of the keys to improved productivity in biopharmaceutical R&D. Through efficient data integration, researchers and program directors can rapidly discover relationships that enable them to make better and faster decisions about disease targets and drug compounds. Jumper delivers substantial gains for drug discovery research by rapidly cleansing and converting data for more efficient determination of targets.

SEARCH. Given the time, effort, funding and resources required for drug discovery research, substantial gains can be achieved by more focused and efficient selection of targets and leads. Providing more focused search, particularly for genomic and proteomic information, should contribute to more effective selection of drug leads and shorter time to market for those drug compounds. Jumper delivers innovative semantic technology that allows scientists to ask complex, ad-hoc queries of aggregated data for more focused leads.